Core Insights - Serina Therapeutics, Inc. has successfully closed a $5 million financing round from strategic shareholders to support the development of its lead clinical candidate SER-252 for Advanced Parkinson's disease [1][2] - The financing reflects investor confidence in SER-252's potential to provide continuous dopaminergic stimulation, which may offer significant clinical benefits for patients [2] - SER-252 is designed to reduce levodopa-related motor complications and improve patient comfort through a long-acting subcutaneous injection [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [5] - The company utilizes its proprietary POZ Platform, which enhances drug delivery and efficacy across various therapeutic modalities [5] Product Details - SER-252 (POZ-apomorphine) is an investigational therapy that aims to provide continuous dopaminergic stimulation, potentially reducing dyskinesia in advanced Parkinson's patients [3] - The drug leverages Enable Injections' enFuse wearable drug delivery platform for improved patient experience [3] Technology Platform - The POZ Platform is based on a synthetic polymer that allows for better control over drug loading and release rates, addressing limitations of existing drugs [4] - This technology has the potential to enhance the therapeutic profiles of various drug candidates, including small molecules and RNA-based therapeutics [4]

Core Points - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing its proprietary POZ Platform™ for drug optimization [3] - The CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025 [1] - The company is headquartered in Huntsville, Alabama, and is developing a pipeline of drug candidates for neurological diseases and other indications [3] Company Overview - Serina Therapeutics is developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other conditions [3] - The POZ Platform™ has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [3] - The company operates from the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama [3] Event Information - A live webcast of the CEO's presentation will be available for registered attendees, with an archived replay accessible for 90 days post-event [2]

HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights. "We are encouraged by the progress we've made this year. Our partnership with Enable Injections' wearable technology, combined with our POZ optimization technology, is poised to deliver ...

Parkinson's Disease Treatment - SER-252 (POZ-Apomorphine) is projected to address a significant unmet need in the advanced Parkinson's disease market, with a commercial opportunity estimated between $2.1 billion and $3.3 billion[10]. - The lead program SER-252 is expected to enter clinical trials in 2025, focusing on continuous dopaminergic stimulation for advanced Parkinson's disease[4]. - The market for advanced Parkinson's disease treatments is growing at approximately 1.5% per year, with around 210,000 patients in the US and 150,000 in the EU and UK inadequately controlled on current therapies[18]. - SER-252 aims to provide a differentiated treatment option with a dosing regimen of twice per week via subcutaneous injection, avoiding the need for electronic infusion pumps[10]. - The product development plan includes a Phase 1b trial in advanced Parkinson's disease patients, with interim data expected in the second half of 2026[30]. - Phase 1 trial of SER-252 in advanced Parkinson's disease is set to initiate in Q3 2025, with interim readouts expected in 1Q 2026[47]. - Phase 1b trial for SER-252 in advanced Parkinson's patients is scheduled for 2H 2025, providing early efficacy readout[49]. Drug Development and Partnerships - The partnership with Pfizer in the RNA vaccine field represents a strategic collaboration to enhance product development and market reach[34]. - The company has a strong track record in drug development, with cumulative sales across 32 FDA-approved PEGylated drugs exceeding $25 billion[4]. - The first license deal for RNA products was executed in Q4 2023, indicating a proactive approach to expanding the company's portfolio in the biotechnology sector[34]. - The company is exploring partnering opportunities in RNA delivery/targeting and ADC optimization[48]. - POZ platform partnerships in RNA and ADCs are anticipated to be established by 2025/26[47]. Financial Position and Projections - Preliminary cash position at year-end 2024 is projected to be $3.4 million, with recent funding of $10 million extending runway through 1H 2025[48]. - Sale of UniverXome subsidiary in Q4 2024 will eliminate all corporate debt[49]. - Lead IND candidate SER-252 has a peak sales potential estimated between $2.1 billion and $3.3 billion[48]. POZ Platform and Technology - The POZ platform enables optimized drug delivery with reduced immunogenicity and improved safety profiles compared to traditional methods[7]. - SER-252 is designed to minimize adverse skin reactions, a common issue with existing therapies, as demonstrated in preclinical studies[13]. - Preclinical data for POZ platform optimization of ADCs is expected in 1Q 2025[47]. - POZ-RNA and POZ-ADCs programs are in R&D with partners for RNA therapeutics and oncology, respectively[51]. - SER-2xx candidates are in proof of concept stages for CNS and cardiology indications[50].

OR FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 Serina Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-143682 ...

HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight fi ...

Core Insights - The FDA has provided constructive feedback on Seres Therapeutics' SER-155 development plans, supporting a Phase 2 study with a primary efficacy endpoint focused on reducing bloodstream infections (BSIs) post-allo-HSCT [1][2][4] - Seres Therapeutics plans to submit a proposed protocol for the next SER-155 study to the FDA in Q2 2025, incorporating the agency's feedback [1][2] - SER-155 has shown a 77% relative risk reduction in BSIs in a Phase 1b study, along with reduced systemic antibiotic exposure and lower incidence of febrile neutropenia [2][4] Company Overview - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving outcomes for medically vulnerable populations [5] - The company has received Breakthrough Therapy designation for SER-155, targeting the reduction of BSIs in allo-HSCT patients, and Fast Track designation for reducing infection risk and graft-versus-host disease [5][4] - SER-155 is designed to decolonize gastrointestinal pathogens and improve immune tolerance in patients undergoing allo-HSCT for hematological malignancies [3][5] Future Development Plans - The next study design for SER-155 may retain elements from the previous Phase 1b trial, which demonstrated significant clinical benefits [2][4] - The company is actively seeking partnerships to support the further development of SER-155 in allo-HSCT [2]

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of developme ...

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clini ...

Core Viewpoint - Serina Therapeutics has successfully closed the second tranche of a $10 million equity financing, enabling the advancement of its investigational drug SER-252 into Phase 1 clinical trials for advanced Parkinson's disease patients in the second half of 2025 [1][3]. Financing Details - The second tranche involved a $5 million investment from strategic shareholder JuvVentures, with Serina issuing 500,000 shares at $10 per share, reflecting a 113% premium over the closing price on January 31, 2025 [2]. - Additionally, warrants for up to 755,728 shares at an exercise price of $18.00 per share were issued to JuvVentures [2]. Product Development - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [4]. - The drug leverages Enable Injections' enFuse™ wearable drug delivery platform for enhanced patient comfort and convenience [4]. Technology Overview - Serina's proprietary POZ Platform™ utilizes a synthetic polymer to improve drug loading control and release precision, aiming to maintain stable blood levels of therapeutic agents [5]. - The POZ technology has potential applications across various drug delivery formulations, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery [6]. Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases, utilizing its POZ Platform™ to enhance the efficacy and safety profiles of various therapeutic modalities [7].